There are currently 3063 clinical trials in New York, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including Memorial Sloan Kettering Cancer Center, Columbia University Medical Center, Icahn School of Medicine at Mount Sinai and Columbia University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Implementing Models for Mechanical Circulatory Support Presurgical Assessment in Congenital Heart Disease Treatment
NCT03891160
Recruiting
The purpose of this research study is to look at the advantages of using a 3D printed heart model for surgical planning in children who have been diagnosed with Congenital Heart Disease (CHD) and clinical heart failure and will undergo a ventricular assist device (VAD) placement. The investigators want to study the correlation of having a 3D printed model with improvement in patient outcomes and compare those with patients who have had a VAD placement without a 3D model.
Gender:
ALL
Ages:
All
Trial Updated:
07/03/2024
Locations: Columbia University, New York, New York +1 locations
Conditions: Congenital Heart Disease
Register for Updates
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
NCT03391778
Recruiting
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Gender:
ALL
Ages:
All
Trial Updated:
07/02/2024
Locations: Memorial Sloan Kettering Cancer Center - New York, New York, New York
Conditions: Neoplasms
Register for Updates
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Recruiting
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Weill Cornell Medicine, New York, New York
Conditions: Endometrial Cancer
Register for Updates
Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
NCT05519111
Recruiting
A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Mount Sinai Hospital, New York, New York
Conditions: Sickle Cell Disease
Register for Updates
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519
Recruiting
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Epithelial Ovarian Cancer, BRCA2 Mutation, ER+ Breast Cancer, Castrate Resistant Prostate Cancer, BRCA1 Mutation, BRCA Mutation, Endometrial Cancer, Colorectal Cancer, Gastric Cancer
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York +3 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
The Impact of Glomerular Disorders on Bone Quality and Strength
NCT04528446
Recruiting
The primary objectives of this study are to: (1) determine the impact of glomerular disease on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone strength in glomerular disease.
Gender:
ALL
Ages:
Between 5 years and 55 years
Trial Updated:
06/28/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Glomerular Disease, Bone Diseases, Metabolic, Bone Fracture
Register for Updates
Efficacy of STABL Virtual Rehabilitation
NCT05556850
Recruiting
The purpose of the proposed study is to evaluate the efficacy of STABL rehabilitation vs in-person rehabilitation following meniscectomy or synovectomy. STABL is a digital health platform that uses computer-vision technology to facilitate at-home post-op recovery for patients while enabling remote monitoring by their surgeon.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/28/2024
Locations: NYU Langone Health, New York, New York
Conditions: Physical Therapy
Register for Updates
Postpartum Low-Dose Aspirin and Preeclampsia
NCT03667326
Recruiting
The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Preeclampsia Postpartum
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Kings County Hospital, New York, New York
Conditions: Breast Cancer
Register for Updates
Decision Aid (DA) for Renal Patients
NCT05387863
Recruiting
The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized benefit/harm estimates to patients and promote patient-centered treatment of renal tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: NYU Langone Health, New York, New York
Conditions: Kidney Tumor, Renal Cancer
Register for Updates
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
NCT05929976
Recruiting
Nutritional status is a measurable and modifiable factor that is often not considered during treatment and its clinical impact undervalued due in part to the heavy demands on clinicians in low and middle income countries to deliver therapy to large numbers of patients. The proposed study will create a biobank of clinical data and biological specimens which will foster future studies on cancer progression and prognosis as well as toxicities during treatment which may impact survivorship and late-... Read More
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
06/25/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Acute Lymphoblastic Leukemia, Nutrition Aspect of Cancer, Microtia, Genetic Predisposition
Register for Updates